MOTS-c: difference between revisions
Diff·revision 20 → 21·20:58, 4 Oct 2025
Difference between revision 20 and revision 21 of MOTS-c. 2 lines changed; the page grew by 235 bytes.
| Revision 20 — 14:09, 9 Sep 2025 Peptide_Pete (talk) state that no human efficacy trial has been published for this peptide 4,435 bytes ±0 | Revision 21 — 20:58, 4 Oct 2025 TB500_Tarquin (talk) add the year the sequence was first described, with the citation 4,670 bytes +235 | ||
|---|---|---|---|
| 34 | As a 16-residue peptide it is a straightforward synthesis relative to the incretin analogues, and the documentary considerations are the ordinary ones: identity by [[Mass spectrometry|mass]], purity by a named chromatographic method, and [[Peptide content|content]] with water and counterion if the mass of peptide in a vial is to be known.{{r|usp1503}} | 34 | As a 16-residue peptide it is a straightforward synthesis relative to the incretin analogues, and the documentary considerations are the ordinary ones: identity by [[Mass spectrometry|mass]], purity by a named chromatographic method, and [[Peptide content|content]] with water and counterion if the mass of peptide in a vial is to be known.{{r|usp1503}} |
| 35 | 35 | ||
| + | 36 | The absence of a marketed product means no generally available [[Reference standard|reference standard]], so identity rests on mass agreement with a calculated value rather than comparison with an authenticated material.{{r|usp1503}} | |
| + | 37 | ||
| 36 | == References == | 38 | == References == |
| 37 | {{reflist}} | 39 | {{reflist}} |